Evidence map›Paper›PMID 27641835›Full record

ArticlePediatric rheumatology online journal2016

Parents' information needs and influential factors when making decisions about TNF-α inhibitors.

Ellen A Lipstein, Daniel J Lovell, Lee A Denson, Sandra C Kim, Charles Spencer, Maria T Britto

Abstract read
In one paragraph

Article in Pediatric rheumatology online journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Article
  4. Shared decision making in IBD: A novel approach to trial consent and timing.Contemporary clinical trials communications · 2019
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ellen A LipsteinDivision of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA. ellen.lipstein@cchmc.org.
Daniel J LovellDivision of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, USA.
Lee A DensonDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, USA.
Sandra C KimDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Nationwide Children's Hospital, Columbus, USA.
Charles SpencerDivision of Rheumatology, Department of Pediatrics, Nationwide Children's Hospital, Columbus, USA.
Maria T BrittoDivision of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA.

Funding

Shared Decision Making In Pediatric Chronic Conditions: Biologics in IBD and JIAK23HD073149 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI LIPSTEIN, ELLEN A · 2012 to 2016
$656k
NICHD NIH HHS K23 HD073149
6 · The paper itself

Abstract

backgroundParents struggle when making treatment decisions for children with arthritis or other chronic conditions. Understanding their decision-making process is an essential step towards improving the decision-making experience. The objective of this study was to describe parents' information needs and the influences on their decision making about treatment with TNF-α inhibitors.

methodsSurvey domains were developed based on qualitative data and cognitive interviewing. We mailed the survey to parents of children with juvenile idiopathic arthritis or inflammatory bowel disease who had initiated treatment with TNF-α inhibitors in the prior 2 years. Data were analyzed using descriptive and non-parametric statistics.

resultsSurvey response rate was 54.9 %. Each item had <2 % missing responses. Parents used an array of information sources when deciding about treatment with TNF-α inhibitors. Resources other than their child's specialist were most often used to increase confidence in parents' decisions or because they wanted to know more about other people's experiences being treated with TNF-α inhibitors, rather than due to a lack of understanding. All but two (cost and route of administration) of the influential decision factors were very or extremely important to the majority of participants with factors related to long-term side effects, treatment efficacy, and disease impact being most important.

conclusionsThis study describes parents' information needs and influential factors in treatment decision making. Results suggest that future work should be aimed at helping families weigh risks and benefits, such as through decision support interventions, as well as developing opportunities to include people beyond the family and physician in the decision-making process.

Indexed as

Arthritis, JuvenileInflammatory Bowel DiseasesAdolescentChildDecision MakingFemaleHumansInterview, PsychologicalMaleMedication Therapy ManagementParentsProfessional-Family RelationsRisk AssessmentSocioeconomic FactorsSurveys and QuestionnairesTumor Necrosis Factor-alphaTumor Necrosis Factor-alpha

Identifiers

PMID27641835
PMCPMC5024421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.